Study identifier:ACE-LY-002
ClinicalTrials.gov identifier:NCT02112526
EudraCT identifier:2014-001341-25
CTIS identifier:N/A
An Open-label, Phase 1b Study of ACP 196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Phase 1
No
Acalabrutinib
All
21
Interventional
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2024 by AcertaPharma
AcertaPharma
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Acalabrutinib | - |